PhRMA is moving
PhRMA is relocating its offices effective April 1 to 950 F Street NW, Suite 300, Washington, D.C. 20004. The new office will have additional space and will allow the trade group to consolidate its departments under one roof. Included in the upgrade is a state-of-the-art broadcast studio that will enable PhRMA to respond to news events but also create programming content for cable television and the Internet...
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.